Invitae Co. (NYSE:NVTA) Receives Consensus Rating of "Hold" From Brokerages
Invitae Co. (NYSE:NVTA) Receives Consensus Rating of "Hold" From Brokerages
Invitae Co. (NYSE:NVTA – Get Rating) has been assigned a consensus rating of "Hold" from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell recommendation and nine have issued a hold recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $10.33.
據市場評級公司報道，Invitae Co.(紐約證券交易所股票代碼：NVTA-GET Rating)已被涵蓋該公司的13家研究公司一致給予“持有”評級。4名研究分析師對該股給予了賣出建議，9名分析師對該公司提出了持有建議。在過去一年對該股進行評級的券商中，12個月目標價的平均水平為10.33美元。
Several equities analysts have recently commented on the company. Credit Suisse Group initiated coverage on Invitae in a research note on Wednesday, August 24th. They issued an "underperform" rating on the stock. Benchmark cut shares of Invitae from a "buy" rating to a "hold" rating in a research report on Tuesday, July 19th. Cowen lowered shares of Invitae from an "outperform" rating to a "market perform" rating in a report on Tuesday, July 26th. Cowen cut shares of Invitae from an "outperform" rating to a "market perform" rating in a research report on Tuesday, July 26th. Finally, SVB Leerink boosted their target price on Invitae from $2.50 to $3.00 and gave the company a "market perform" rating in a research report on Wednesday, November 9th.
幾位股票分析師最近對該公司發表了評論。瑞士信貸集團在8月24日星期三的一份研究報告中啟動了對Invitae的報道。他們對該股給予了“表現不佳”的評級。在7月19日星期二的一份研究報告中，Benchmark將Invitae的股票評級從“買入”下調至“持有”。在7月26日週二的一份報告中，考恩將Invitae的股票評級從“跑贏大盤”下調至“市場表現”。在7月26日週二的一份研究報告中，考恩將Invitae的股票評級從“跑贏大盤”下調至“市場表現”。最後，SVB Leerink在11月9日(週三)的一份研究報告中將Invitae的目標價從2.50美元上調至3.00美元，並給予該公司“市場表現”評級。
Invitae Price Performance
Invitae性價比
NVTA stock opened at $3.17 on Tuesday. Invitae has a 1 year low of $1.83 and a 1 year high of $22.35. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.42 and a quick ratio of 6.07. The firm has a market capitalization of $769.98 million, a PE ratio of -0.23 and a beta of 1.59. The business has a 50 day simple moving average of $2.67 and a 200-day simple moving average of $3.04.
NVTA股價週二開盤報3.17美元。Invitae的一年低點為1.83美元，一年高位為22.35美元。該公司的負債權益比為4.12，流動比率為6.42，速動比率為6.07。該公司市值為7.6998億美元，市盈率為-0.23，貝塔係數為1.59。該業務的50日簡單移動均線切入位在2.67美元，200日簡單移動均線切入位在3.04美元。
Institutional Investors Weigh In On Invitae
機構投資者在Invitae上發表看法
Several institutional investors have recently added to or reduced their stakes in the business. Arizona State Retirement System lifted its position in Invitae by 4.6% in the first quarter. Arizona State Retirement System now owns 55,072 shares of the medical research company's stock valued at $439,000 after acquiring an additional 2,425 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Invitae by 25.1% in the 2nd quarter. Mackenzie Financial Corp now owns 13,948 shares of the medical research company's stock valued at $34,000 after purchasing an additional 2,795 shares during the last quarter. Private Advisor Group LLC lifted its holdings in shares of Invitae by 9.7% in the 1st quarter. Private Advisor Group LLC now owns 32,282 shares of the medical research company's stock valued at $258,000 after purchasing an additional 2,845 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Invitae by 42.1% in the 1st quarter. SG Americas Securities LLC now owns 10,341 shares of the medical research company's stock valued at $82,000 after purchasing an additional 3,062 shares during the period. Finally, Envestnet Asset Management Inc. grew its stake in Invitae by 5.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 63,738 shares of the medical research company's stock worth $508,000 after buying an additional 3,096 shares during the last quarter. Hedge funds and other institutional investors own 88.27% of the company's stock.
幾家機構投資者最近增持或減持了該公司的股份。亞利桑那州退休制度在第一季度將其在Invitae的頭寸提高了4.6%。亞利桑那州退休系統現在擁有55,072股這家醫療研究公司的股票，價值439,000美元，在上個季度額外購買了2,425股。Mackenzie Financial Corp在第二季度增持了Invitae股票25.1%。麥肯錫金融公司(Mackenzie Financial Corp)目前持有這家醫療研究公司13,948股票，價值34,000美元，此前該公司在上個季度又購買了2,795股票。Private Advisor Group LLC在第一季度增持了9.7%的Invitae股票。Private Advisor Group LLC現在擁有這家醫療研究公司32,282股股票，價值258,000美元，上個季度又購買了2,845股。SG America Securities LLC在第一季度將其在Invitae股票的頭寸增加了42.1%。在此期間，SG America Securities LLC又購買了3,062股，目前持有這家醫療研究公司10,341股股票，價值82,000美元。最後，Envestnet Asset Management Inc.在第一季度增持了Invitae 5.1%的股份。Envestnet Asset Management Inc.現在持有這家醫療研究公司63,738股股票，價值508,000美元，上個季度又購買了3,096股。對衝基金和其他機構投資者持有該公司88.27%的股票。
About Invitae
關於Invitae
(Get Rating)
(獲取評級)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
Invitae公司是一家醫學遺傳學公司，將遺傳信息整合到主流醫學中，以改善美國、加拿大和國際上人們的醫療保健。該公司提供各種臨牀領域的基因測試，包括遺傳癌、心臟病學、神經病學、兒科、腫瘤學、代謝疾病和罕見疾病；數字健康解決方案；以及健康數據服務。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- Wayfair Still Has Its Fair Share of Issues
- Take Two Interactive Software Stock is Taking One Step Back
- This Mid-Cap Tech Stock Embodies Diversified Growth
- Why did NIO take a $581.11 million loss last quarter?
- Is It Time To Take A Ride With Joby Aviation's EV Innovations?
- 免費獲取StockNews.com關於Invitae的研究報告(NVTA)
- WayFair仍有其公平份額的問題
- 交互軟件股票後退一步
- 這隻中型科技股體現了多元化的增長
- 為什麼上個季度蔚來虧損5.811億美元？
- 是時候與Joby Aviation的電動汽車創新一起兜風了嗎？
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.
接受《邀請日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Invitae和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。